Back to Search
Start Over
Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches
- Source :
- Donken, R, Hoes, J, Knol, M J, Ogilvie, G S, Dobson, S, King, A J, Singer, J, Woestenberg, P J, Bogaards, J A, Meijer, C J L M & De Melker, H E 2020, ' Measuring vaccine effectiveness against persistent HPV infections : a comparison of different statistical approaches ', BMC Infectious Diseases, vol. 20, no. 1, 482 . https://doi.org/10.1186/s12879-020-05083-7, BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-11 (2020), BMC Infectious Diseases, 20(1):482. BioMed Central, BMC Infectious Diseases, BMC Infectious Diseases, 20(1):482. BioMed Central Ltd
- Publication Year :
- 2020
- Publisher :
- BioMed Central, 2020.
-
Abstract
- Background Persistent high-risk human papillomavirus (HPV) infection is endorsed by the World Health Organization as an intermediate endpoint for evaluating HPV vaccine effectiveness/efficacy. There are different approaches to estimate the vaccine effectiveness/efficacy against persistent HPV infections. Methods We performed a systematic literature search in Pubmed to identify statistical approaches that have been used to estimate the vaccine effectiveness/efficacy against persistent HPV infections. We applied these methods to data of a longitudinal observational study to assess their performance and compare the obtained vaccine effectiveness (VE) estimates. Results Our literature search identified four approaches: the conditional exact test for comparing two independent Poisson rates using a binomial distribution, Generalized Estimating Equations for Poisson regression, Prentice Williams and Peterson total time (PWP-TT) and Cox proportional hazards regression. These approaches differ regarding underlying assumptions and provide different effect measures. However, they provided similar effectiveness estimates against HPV16/18 and HPV31/33/45 persistent infections in a cohort of young women eligible for routine HPV vaccination (range VE 93.7–95.1% and 60.4–67.7%, respectively) and seemed robust to violations of underlying assumptions. Conclusions As the rate of subsequent infections increased in our observational cohort, we recommend PWP-TT as the optimal approach to estimate the vaccine effectiveness against persistent HPV infections in young women. Confirmation of our findings should be undertaken by applying these methods after longer follow-up in our study, as well as in different populations.
- Subjects :
- Pediatrics
SUSTAINED EFFICACY
Poisson distribution
DOUBLE-BLIND
Immunogenicity, Vaccine
0302 clinical medicine
Medical microbiology
Prevalence
Longitudinal Studies
030212 general & internal medicine
Generalized estimating equation
CROSS-PROTECTIVE EFFICACY
Human papillomavirus 18
Follow-up
Vaccination
YOUNG-WOMEN
HPV-16/18 AS04-ADJUVANTED VACCINE
Exact test
Treatment Outcome
Infectious Diseases
PATRICIA RANDOMIZED-TRIAL
030220 oncology & carcinogenesis
Cohort
symbols
Female
Research Article
Adult
HPV
Human papillomavirus
medicine.medical_specialty
Adolescent
Persistent infection
lcsh:Infectious and parasitic diseases
Young Adult
03 medical and health sciences
symbols.namesake
CERVICAL COINFECTION
medicine
Humans
lcsh:RC109-216
Human papillomavirus 31
Papillomavirus Vaccines
Poisson regression
PARTICLE VACCINE
HUMAN-PAPILLOMAVIRUS TYPE-16
HPV vaccination
business.industry
Papillomavirus Infections
Binomial distribution
Observational study
business
Follow-Up Studies
Subjects
Details
- Language :
- English
- ISSN :
- 14712334
- Database :
- OpenAIRE
- Journal :
- Donken, R, Hoes, J, Knol, M J, Ogilvie, G S, Dobson, S, King, A J, Singer, J, Woestenberg, P J, Bogaards, J A, Meijer, C J L M & De Melker, H E 2020, ' Measuring vaccine effectiveness against persistent HPV infections : a comparison of different statistical approaches ', BMC Infectious Diseases, vol. 20, no. 1, 482 . https://doi.org/10.1186/s12879-020-05083-7, BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-11 (2020), BMC Infectious Diseases, 20(1):482. BioMed Central, BMC Infectious Diseases, BMC Infectious Diseases, 20(1):482. BioMed Central Ltd
- Accession number :
- edsair.doi.dedup.....dd6816bbdbbcfa1b51f8984ecc1ec90c
- Full Text :
- https://doi.org/10.14288/1.0392353